Home / People / Alasdhair McDonald
Alasdhair McDonald

Alasdhair McDonald


CMS Cameron McKenna Nabarro Olswang LLP
Cannon Place
78 Cannon Street
United Kingdom
Languages English, Japanese

Alasdhair is an Intellectual Property solicitor in CMS's award-winning IP team. He has particular experience in conducting patent litigation and dispute resolution in the pharmaceutical and technology sectors. 

Alasdhair has gained in-house experience with the Global IP Litigation team of a major pharmaceutical company and at one of the world's largest luxury goods companies. He holds a degree in biological sciences and the Oxford University Diploma in IP Law and Practice. He trained and worked with Olswang LLP prior to its merger with CMS.

more less

Relevant experience

  • Napp Pharmaceutical Holdings Ltd. v Dr Reddy’s Laboratories (UK) Ltd. and Sandoz Ltd [2016] EWHC 1517 (Pat) (assisting Sandoz in its successful defence of a patent infringement action brought in respect of buprenorphine transdermal patch, and follow-on damages enquiry resulting in a four-week trial).
  • Clearswift Ltd v Glasswall (IP) Ltd [2018] EWHC 2442 (Pat) - patent revocation action in relation to anti-malware technologies.
  • Edwards Lifesciences LLC v Boston Scientific Scimed Inc [2017] EWHC 405 (Pat) (a patent invalidity action and infringement action regarding transcatheter heart valves).
  • Warner-Lambert Company LLC v Sandoz GmBH, Sandoz Limited and Lloyds Pharmacy Limited (second medical use patent litigation regarding pregabalin).
  • JW Spear & Sons Ltd & Another v Zynga, Inc [2013] EWHC 3348 (Ch).
  • JW Spear & Son Ltd, Mattel Inc and Mattel UK Ltd v Zynga Inc [2013] EWCA Civ 1175.
  • Resolution v Lundbeck (escitalopram patent).
  • Numerous antipiracy cases for a global software house.
  • A gaming company on a dispute regarding the ownership and infringement of trade mark, copyright and passing off rights.
  • Online gambling and social gaming company, Gamesys, on a complex disposal and licensing transaction with a value of over £400 million; and
  • Orchard Therapeutics on its collaboration with various academic institutions to fund and develop gene therapy treatments for orphan diseases.
more less


  • 2015 - Diploma in Intellectual Property Law and Practice, University of Oxford, Oxford.
  • 2010 - Graduate Diploma in Law, BPP Law School, Leeds.
  • 2009 - Graduate Diploma in Law, BPP Law School, Leeds.
  • 2008 - Biological Sciences BSc. (Hons), The University of Manchester, Manchester.
more less


  • Case Review: GMP-Orphan v European Commission (Vol 17 Iss 2 BSLR)
  • Bioscience Law Review Volume 17 Issue 2 
  • Orphan Exclusivity (Vol 17 Iss 3 BSLR)
  • Bioscience Law Review Volume 17 Issue 3 
more less


Show only
26 June 2020
Court of Ap­peal re­fuses in­junc­tion in Neur­im v Mylan
We re­cently re­por­ted on the High Court judg­ment of Mr Justice Mar­cus Smith in Neur­im Phar­ma­ceut­ic­als (1991) Lim­ited and Flynn Pharma Lim­ited v Gen­er­ics UK Lim­ited (t/a Mylan) [2020] EWHC 1362 (Pat) in...
11 June 2020
Pat­ents Court re­fuses to grant in­ter­im in­junc­tion in phar­ma­ceut­ic­al pat­ents...
In a re­cent Pat­ents Court in­ter­im hear­ing con­cern­ing phar­ma­ceut­ic­al products, Mr Justice Mar­cus Smith re­fused an ap­plic­a­tion for an in­ter­im in­junc­tion. The judg­ment marks an ex­cep­tion to the “rule of...
08 June 2020
Pat­ents Court Con­firms Onus to “Clear the Way” and Factors Giv­ing Rise...
Birss J has handed down an in­ter­im judg­ment in the Pat­ents Court which con­firms the ex­pect­a­tion on gen­er­ic phar­ma­ceut­ic­al com­pan­ies to “clear the way”, in ad­di­tion to factors which give rise to an...
28 May 2020
The im­pact of Brexit on In­tel­lec­tu­al Prop­erty Rights
Al­though the UK with­drew from the EU earli­er this year the im­pact will not be felt un­til the trans­ition­al peri­od ex­pires on 31 Decem­ber 2020. From that date the UK will no longer re­main sub­ject to EU...
11 October 2019
Case Com­ment: GMP Orphan v Com­mis­sion, first pub­lished by Law­text.com
This case com­ment was first pub­lished by law­text.com in Bios­cience Law Re­view, Volume 17, Is­sue 2. Its con­tent has been re­pro­duced with the per­mis­sion of law­text.com. GMP-Orphan v European Com­mis­sion...
08 October 2019
CJEU re­fuses to shed light on third party SPC po­s­i­tion based on hy­po­thet­ic­al...
In­tro­duc­tion Fol­low­ing re­fer­ral from the High Court of Eng­land and Wales, the Court of Justice of the European Uni­on (the “CJEU”) re­fused to give a pre­lim­in­ary rul­ing on wheth­er a pat­entee can ob­tain...
26 February 2019
Valid­ity of pat­ent con­sidered at pre­lim­in­ary in­junc­tion stage
1. In­tro­duc­tion In a re­cent judg­ment, the High Court con­sidered the valid­ity of a pat­ent at the pre­lim­in­ary in­junc­tion stage, on the basis of a sum­mary judg­ment ap­plic­a­tion brought by Dr Reddy’s Labor­at­or­ies...